We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
TIDMEVG
RNS Number : 7759A
Evgen Pharma PLC
02 January 2018
2 January 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Total Voting Rights
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, makes the following notification in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1.
As at 29 December 2017 the Company's issued share capital consists of 93,276,858 Ordinary Shares of 0.25p each.
The total number of voting rights in the Company is 93,276,858 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries
Evgen Pharma plc c/o +44 (0) 20 7466 5000 Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com Buchanan Mark Court, Sophie Wills, Stephanie Watson +44 (0) 20 7466 5000 Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) John Howes, Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
Notes for editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRDLLFBVFFZBBL
(END) Dow Jones Newswires
January 02, 2018 12:44 ET (17:44 GMT)
1 Year Evgen Pharma Chart |
1 Month Evgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions